Department of Neurology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Clin Neurophysiol. 2012 Sep;123(9):1886-90. doi: 10.1016/j.clinph.2012.01.017. Epub 2012 Mar 3.
Tacrolimus (FK506) is a macrolide T-cell immunomodulator used to treat myasthenia gravis (MG). Besides immunosuppression, tacrolimus has been reported to have the potential to increase muscle strength by enhancing ryanodine receptor (RyR) function. However, few attempts have been made to demonstrate the early effect of tacrolimus as an RyR enhancer in clinical investigation.
In 20 MG patients, masseteric compound muscle action potential (CMAP) and mandibular movement-related potentials (MRPs) were recorded simultaneously after stimulating the trigeminal motor nerve with a needle electrode. The excitation-contraction (E-C) coupling time (ECCT) was calculated by the latency difference between CMAP and MRP. Bite force was measured using a pressure-sensitive sheet. Serial assessments of % decrement in masseteric repetitive nerve stimulation (RNS), ECCT and bite force were performed before and within 4 weeks of tacrolimus (3 mg day(-1)) treatment. The median (mean, range) interval of assessment was 2 (2.4, 1-4) weeks. We also measured serum antibodies against RyR, acetylcholine receptor and muscle-specific receptor tyrosine kinase.
Bite force increased after tacrolimus treatment accompanying clinical improvement assessed by Myasthenia Gravis Foundation of America classification, but the bite force difference did not reach statistical significance. Wilcoxon matched-pairs signed-ranks test detected a significant ECCT shortening in 12 patients assessed after 1-2 weeks of tacrolimus treatment as well as in eight patients assessed after 3-4 weeks. In contrast, masseteric CMAP and % decrement showed no significant changes after short-term tacrolimus treatment.
Tacrolimus induces ECCT shortening accompanying clinical improvement despite no improvement in % decrement within 2 weeks.
This early effect of tacrolimus may imply a pharmacological enhancement of RyR function to improve E-C coupling in MG.
他克莫司(FK506)是一种大环内酯类 T 细胞免疫调节剂,用于治疗重症肌无力(MG)。除了免疫抑制作用外,他克莫司还被报道具有通过增强兰尼碱受体(RyR)功能来增加肌肉力量的潜力。然而,在临床研究中,很少有尝试来证明他克莫司作为 RyR 增强剂的早期作用。
在 20 例 MG 患者中,使用针电极刺激三叉运动神经后,同时记录咬肌复合肌肉动作电位(CMAP)和下颌运动相关电位(MRP)。通过 CMAP 和 MRP 的潜伏期差异计算兴奋-收缩(E-C)偶联时间(ECCT)。使用压力敏感片测量咬合力。在他克莫司(3mg/天)治疗前和治疗后 4 周内,连续评估咬肌重复神经刺激(RNS)、ECCT 和咬合力的%递减。评估的中位数(均值,范围)间隔为 2(2.4,1-4)周。我们还测量了血清抗 RyR、乙酰胆碱受体和肌肉特异性受体酪氨酸激酶抗体。
在接受他克莫司治疗后,咬合力增加,同时根据美国重症肌无力基金会分类评估的临床改善,但咬合力差异没有达到统计学意义。Wilcoxon 配对符号秩检验检测到在接受他克莫司治疗 1-2 周的 12 例患者以及在接受治疗 3-4 周的 8 例患者中,ECCT 明显缩短。相比之下,在接受短期他克莫司治疗后,咬肌 CMAP 和%递减没有明显变化。
尽管在 2 周内%递减没有改善,但他克莫司诱导 ECCT 缩短,同时伴有临床改善。
他克莫司的这种早期作用可能意味着 RyR 功能的药理学增强,以改善 MG 中的 E-C 偶联。